Pipeline

Nav1.7 is a genetically validated pain target outside of the opiate signaling pathway. Candidate ASOs are currently being considered for intractable cancer pain, small fiber neuropathy, and moderate-to-severe lumbosacral radiculopathy.

Nav1.8 is a genetically validated pain target outside of the opiate signaling pathway. Candidate ASOs are currently being considered for intractable cancer pain, small fiber neuropathy, and moderate-to-severe lumbosacral radiculopathy.

Nav1.7 and Nav1.8 are genetically validated pain targets outside of the opiate signaling pathway. Candidate ASOs are currently being considered for intractable cancer pain, small fiber neuropathy, and moderate-to-severe lumbosacral radiculopathy.

Nav1.7 is a genetically validated pain target outside of the opiate signaling pathway. Candidate small molecules are currently being considered for osteoarthritis.

Dup15q Syndrome is a neurodevelopmental disorder generally characterized by hypotonia, motor delays, intellectual disability, epilepsy, and autism spectrum disorder. Overexpression of the UBE3A gene is thought to be the predominant cause of Dup15q Syndrome.